Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jul 20, 2021 7:57am
272 Views
Post# 33574154

Some Appreciation for Management

Some Appreciation for Management
I have been a grumpy grader of management's investor engagement efforts but think we should also take a moment to show some appreciation for what they have pulled off in NASH. Basically, they created a phase III ready trial out of next to nothing. They have never performed a phase I or II NASH trial and yet they conjured up an asset for shareholders by sheer will power and gutsy calls. Time will tell what that asset will be worth, but it is remarkable that we are even talking about it at this point. If there is anything good that came out of the failure to get Trogarzo launched successfully, it was the necessity to come up with something else to give TH a future, without spending much money, that led to NASH (and cancer). Past and present board members and management team members deserve credit for pulling this off. The market may not like the delay in the trial's start but the fact there is even a trial to start, backed by both main regulatory bodies, is quite an achievement that we should all appreciate. But we still do need better investor engagement so more than just the small number of us on this site can appreciate what has been pulled off.
<< Previous
Bullboard Posts
Next >>